| Theme | Treatment of Acid‒related Diseases -- the Past, Present and Future | |
|---|---|---|
| Title | Treatment of Peptic Ulcers with Antisecretory Drugs | |
| Publish Date | 2017/02 | |
| Author | Kiichi Satoh | Department of Gastroenterology, International University of Health and Welfare Hospital |
| [ Summary ] | The Japanese Society of Gastroenterology (JSGE) revised the evidence‒based clinical practice guidelines for peptic ulcer disease in 2014. Treatment with antisecretory drugs was included in the guidelines. In cases of non‒H. pylori, non‒NSAID (non-steroidal anti-inflammatory drug) ulcers, or H. pylori‒positive patients with no indication for eradication therapy, non‒eradication therapy is provided. The first choice is proton pump inhibitor (PPI), and the second choice is histamine 2‒receptor antagonist (H2RA). After initial therapy, maintenance therapy is provided for the prevention of ulcer relapse, using an H2RA or a mucosal-defensive agent. In cases of NSAID ulcers, the use of NSAIDs is stopped. If NSAID use must continue, the ulcer is treated with a PPI or prostaglandin analog. |
|